Skip to main content

Tag: Export

Australian cannabis companies are growing weary of Canadian imports

As Australia’s domestic medical cannabis market evolves, some companies are becoming frustrated with the country’s ongoing reliance on cannabis imports from Canada.

Still, others say demand is being driven by consumer preference. 

Australia legalized medical cannabis in 2016, and by 2017, Canadian cannabis companies were announcing exports of cannabis oil and flower to the country. Although many of these initial shipments were relatively small (just the equivalent of 200 grams in 2017), by 2021, Canadian companies exported nearly 5,800 kg of cannabis; by 2023, that figure was over 34,000 kg. 

The early reliance on imports came at a time when Australia’s domestic industry was in its infancy. But in late 2024, some of these companies recently told the country’s Sydney Morning Herald that they are struggling to compete with what some characterize as product “dumping”. 

These accusations mirror similar ones levied by the Israeli government earlier this year to the dismay of Global Affairs Canada

Some cannabis companies in Australia say that much of the cannabis being imported from Canada is of lower quality and that the products have fewer checks on quality than what is produced by Australian companies. 

“I have no issue with imports coming here; the issue is that because they have surplus product, they’re dumping it here, which makes things difficult for local cultivators,” Nan-Maree Schoerie, managing director of ECS Botanics, tells the Herald. ECS is an Australian cultivator and manufacturer of medicinal cannabis. 

StratCann also spoke with Schoerie about the issue. She explained that while some of the Canadian cannabis products coming into Australia are good quality, she thinks some companies are unloading lower-quality products from their vaults due to an oversupply in Canada. 

“We have a product that comes into Australia from Canada that is extraordinarily good quality, probably for the extra years of experience,” she tells StratCann. “But there’s also an enormous amount of product that we believe is coming from stockpiling in Canada.

“That product is flooding into Australia. It’s not necessarily fresh, it’s not necessarily great, but they can sell it at a very low price.”

The export market is a good opportunity for Canadian companies to offload lower-quality product, but she notes this pushes the price down in Australia just as it has in Canada. While growers in Australia could get around AU$6 a gram, wholesale, in 2023, Schoerie says in 2024 that has dropped to around $4-4.50. 

“That is a direct consequence of the amount of product that has come in, primarily from Canada.”

Schoerie notes that her own company exports products, as well, and doesn’t blame Canadian companies, or any others for finding markets for their products where they can. 

Ultimately, she says the issue is one created by the Australian government, specifically the agency that oversees Australia’s cannabis for medical purposes program, the Therapeutic Goods Administration (TGA). 

She explains this because the TGA, which requires Australian companies to have GMP compliance, allows companies importing their products into Australia to use a “loophole” to have them packaged in a GMP-compliant facility. She also says the TGA doesn’t have the resources to ensure the facilities that package goods in Canada adhere to Australian requirements. 

Andrew Dowling, the director at an Australian cannabis wholesaler called Phytoca that focuses primarily on imports, pushes back against this argument, saying that being processed in a GMP facility in Canada or Australia is still the same standard. 

“The actual growing of cannabis is not covered under GMP, anywhere in the world, because it’s not a manufacturing activity,” argues Dowlin. “It’s cultivation.” 

The issue of product “dumping”, he says, is one being pushed by companies who simply aren’t meeting the international market’s demands, both in terms of price, but also in terms of quality. 

 “If these governments really had a problem with Canadian imports, there are levers at their disposal that they could be pulling on to turn it off.”

“It’s wrong to claim it’s being dumped. That product is being ordered because there’s a commercial opportunity and the demand is driven by the price point that is unmatched by Australian companies. If Australian companies could find a solution to that, they’d be doing it.”

Deepak Anand, an industry consultant in Canada who assists cannabis companies with exports into countries like Australia, echoes these sentiments.

“Whether it be Germany, Australia, or Israel, Canadian products are of a better quality than domestic supply. This is a reflection of what the market wants rather than this alleged dumping, which hasn’t been proven anywhere. 

“I think this notion of dumping, which was started by the Israelis—it’s catchy and sounds like something nefarious is going on—but the fact of the matter is Canadian products are just of a higher quality so that’s why there’s a demand for it.”

Canadian cannabis companies have indeed been dealing with domestic price compression from an excess of supply that has led many companies to lean into the export market.  Exports are seen as an easier and, at times, more lucrative path to market than selling domestically, since exports are often bulk sales and are not subject to Canada’s federal excise tax of $1 per gram.

The oversupply of cannabis in Canada that has pushed many companies to the export market has, in the past year or so, also had the effect of relieving some of that downward pressure on domestic prices. While exports don’t appear to be slowing down, it’s possible that the international market will begin to find some balance.

Preliminary report: Israel might apply import fees on Canadian cannabis

The Israeli Government has released its preliminary decision regarding accusations that Canadian cannabis companies are dumping low-cost cannabis products in the Israeli medical cannabis market.

The preliminary findings have determined a fair price and profit margin for Canadian companies selling cannabis into the Israeli market. A final version of the report, with finalized recommendations, is expected later this year.  

The commissioner has decided against imposing a temporary guarantee of any levies and will provide his final recommendations on the matter in the investigation’s final findings.

The investigation was announced in January 2024 by the Commissioner for Trade Levies at the Ministry of Economy and Industry, Danny Tal. 

In the course of the investigation, it was determined that the large volume of cannabis sold into the Israeli medical market from Canada was having a significant impact on both the local market and domestic companies’ ability to compete. 

These products, determined Tal’s report, were sold at lower prices that, he argues, do not reflect the normal course of business and at prices that are lower than production costs or from their prices in the Israeli market, especially given the additional costs of exporting cannabis from Canada. 

An example of some of the Canadian cannabis products available in the Israeli market.

Many Israeli cannabis companies told the investigators that they were forced to sell products at or below cost due to competition with lower-priced Canadian cannabis. Producers also said they were forced to destroy large amounts of cannabis they could not sell, in part due to these imports. 

Cannabis Magazine, an online publication in Israel, says that many Israeli medical patients have preferred Canadian cannabis because it is seen as a higher quality than locally-produced products. However, the report also notes that the quality of cannabis from licensed Israeli companies has improved in recent years. 

Israel imported 78,394 kg of cannabis from 2020-2023, with 62,345 kg coming from Canada, or about 80%. Other countries of origin were Portugal, Uruguay, and Uganda. 

The investigation looked into all Canadian cannabis companies selling products into the Israeli market. They specifically visited Organigram, Decibel, and Pure Sunfarms who welcomed investigators to look closer at their facilities and books. 

Once the investigators determined an accepted price and an export price per gram of cannabis, the commissioner calculated overflow rates in the complaint products for each of the three companies that cooperated with the investigation and for the rest of Canada.

Based on these factors, the investigator determined that these companies are entitled to an 8% profit on products sold into their local market. The investigation also determined that a fair price for Canadian cannabis sold into the Israeli market was about $2-8 a gram (in Canadian dollars).

Based on investigations into Canadian production costs, including packaging and shipping, as well as additional export costs, the commissioner recommends a floating levy or tariff of 63% for Decibel, 74% for Pure Sunfarms, 112% for Organigram, and 369% for all other producers.

The preliminary report states that the commission will also submit a report on its findings to the World Trade Organization.

All prices in CAD unless otherwise noted

The floating prices exist, explains a notice by the commissioner (Translated), “when the foreign producer exports the goods at prices lower than their production costs or their price in the country of origin. Such imports are defined in the World Trade Organization as “unfair trade” and according to the WTO’s Export Convention, the country may protect its domestic market in such cases by imposing an export levy, which compares the import price to the price that reflects fair competition.”

“Sales at floating prices,” it continues, “may arise in cases where the foreign manufacturer suffers from excess inventory that is not sold in his local market alongside a limited validity of the goods that affects his ability to store unsold production surpluses, or in cases where he wishes to capture market share in the importing country even at the cost of a continuous damage to his profitability due to long-term considerations, range of penetration and establishment of its activity in foreign markets.”

The report found that Organigram exported about 5,000-1,000 kg of cannabis flower to Israel in 2023. The investigator determined that a fair price for their products on the market was NIS$10-20, or about CAD$3.75-$7.50 per gram. NIS is the new Israeli Shekel.

The investigator found an acceptable price for Decibel’s products in the Israeli market was also about NIS$10-20. Pure Sunfarms’ products were determined to be about NIS$5-15 per gram, or CAD$2-6.

Another recent report shows that the use of medical cannabis in Israel has been declining in the last six months. A similar trend has been emerging in Canada.

The report notes that the Israeli market faces similar challenges to the Canadian market and others around the world, dealing with market contraction after an initial rush, over-supply, and other issues.  

Many Canadian companies have touted their export sales to countries like Israel as a way to command a better price than in the domestic market and deal with the large volume of product in their vaults.

Despite the increased costs associated with exports, which include special approvals and certifications, producers can often find better payment terms in the export market than selling into provincial markets, where payments can take weeks or even months.  

Stay tuned to StratCann for more on this issue as it evolves.

Related Articles